Compare Novo Nordisk A/S (NVO) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Novo Nordisk A/S trades at $45.89 (market cap $207.85B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | VCIT | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $84.82 |
52-Week Low | $35.29 | $81.07 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
